Safety of the extension of use of galacto-oligosaccharides (GOS) as a novel food in food for special medical purposes pursuant to Regulation (EU) 2015/2283 - PubMed (original) (raw)

. 2022 Mar 30;20(3):e07203.

doi: 10.2903/j.efsa.2022.7203. eCollection 2022 Mar.

Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen, Rosangela Marchelli, Monika Neuhäuser-Berthold, Morten Poulsen, Miguel Prieto Maradona, Josef Rudolf Schlatter, Henk van Loveren, Paolo Colombo, Helle Katrine Knutsen

Safety of the extension of use of galacto-oligosaccharides (GOS) as a novel food in food for special medical purposes pursuant to Regulation (EU) 2015/2283

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) et al. EFSA J. 2022.

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto-oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF (β-GOS) is produced from milk lactose using a β-galactosidase derived from Bifidobacterium bifidum and it is proposed to be used in food for special medical purposes (FSMP). The target population is the general population from 4 years of age onwards. GOS produced according to the same production process are already authorised and included in the EU Union list of novel foods. The applicant stated that the maximum daily intake from the use in FSMP is 8.25 g GOS. GOS are already authorised for use in food supplements up to a daily dose of 16.2 g. FSMP containing GOS are not intended to be used if food supplements containing GOS are consumed on the same day. The information provided on the proposed use levels and anticipated intake does not raise safety concerns. The Panel concludes that the proposed extension of use of GOS in FSMP is safe under the proposed conditions of use.

Keywords: FSMP; GOS; Galacto‐oligosaccharides; extension of use; food for special medical purposes; novel food.

© 2022 Wiley‐VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

PubMed Disclaimer

References

    1. Commins SP, James HR, Kelly EA, Pochan SL, Workman LJ, Perzanowski LS, Kocan KN, Fahy JV, Nganga LW, Ronmark ER, Cooper PJ and Platts‐Mills TAE, 2011. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose‐α‐1,3‐galactose. Journal of Allergy and Clinical Immunology, 127, 1286–1293. -PMC -PubMed
    1. Commins SP and Platts‐Mills TAE, 2009. Anaphylaxis syndromes related to a new mammalian crossreactive carbohydrate determinant. Journal of Allergy and Clinical Immunology, 124, 652–657. -PMC -PubMed
    1. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies) , 2010. Scientific Opinion on Dietary Reference Values for carbohydrates and dietary fibre. EFSA Journal 2010; 8(3):1462, 77 pp. 10.2903/j.efsa.2010.1462 -DOI
    1. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies) , 2011. Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro‐intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(12):2472, 13 pp. 10.2903/j.efsa.2011.2472. Available online: www.efsa.europa.eu/efsajournal -DOI
    1. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies) , 2014. Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro‐intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2014;12(7):3756, 13 pp. 10.2903/j.efsa.2014.3756 -DOI

LinkOut - more resources